3464results about "Granular delivery" patented technology

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a synthetic nicotine composition and a preparation method thereof. The nicotine buccal film agent disclosed by the invention is prepared from the following components in parts by weight: 2 to 4 parts of nicotine clathrate compound powder, 0.2 to 0.6 part of phosphatidic acid, 0.1 to 0.3 part of tannic acid, 0.1 to 0.2 part of sodium ascorbate, 0.04 to 0.06 part of tocopherol, 0.01 to 0.02 part of ethylene diamine tetraacetic acid, 2 to 4 parts of povidone and 40 to 80 parts of absolute ethyl alcohol. The synthesized nicotine composition prepared by the invention can effectively relieve the phenomenon that the faster the nicotine is released, the stronger the bitter taste is. Meanwhile, in a high-temperature and high-humidity environment, the stability of nicotine can be effectively maintained, and the oxidation half-life period of nicotine is prolonged.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The invention relates to a composite hydroxypropyl methylcellulose skeleton sustained-release material and a preparation method thereof, and belongs to the technical field of drug sustained release. The sustained-release material is prepared from 70 to 90 parts of hydroxypropyl methylcellulose (HPMC), 10 to 20 parts of sodium alginate, 8 to 15 parts of chitosan, 0.1 to 0.2 part of Omega-3 fatty acid, 0.05 to 0.06 part of vitamin D, 2.5 to 5 parts of soluble calcium salt-zinc salt composite cross-linking agent, 0.5 to 1.5 parts of hydrolyzable cross-linking agent, 3 to 10 parts of enzyme sensitive auxiliary material, 1 to 5 parts of pore-foaming agent and 2 to 8 parts of hydrophobic blocking agent. The preparation method comprises the steps of raw material pretreatment and dry mixing, active component dispersion liquid preparation, wet granulation and primary cross-linking, secondary cross-linking and drying, vacuum drying and size stabilization, curing and packaging and the like. The sustained-release material provided by the invention has the advantages of controllable drug release rate, good mechanical strength and biodegradability, is suitable for sustained-release delivery of Omega-3 fatty acid, vitamin D and other active components, and can improve the bioavailability and stability of drugs.

The invention relates to composition of urolithins comprising urolithins and pectin and formulations of urolithins, specifically chewable formulations, comprising urolithins and a gelling agent. The invention further comprises compositions and chewable formulations comprising urolithins in combination with other active ingredients and processes for the preparation of such compositions and formulations. The invention further comprises methods of using such compositions and formulations in the treatment of conditions and diseases and for the promotion of health and performance, such in the improving muscle function.

The invention relates to a double-framework self-developing embolism system based on iodine modified PNIPAM gel and cross-linked albumin microspheres, which simulates a brick wall-concrete effect through a microsphere-gel composite structure and synergistically improves the embolism strength. A novel TACE treatment system is designed and constructed, multiple effects of tracing, embolism, hypoxia enhanced chemotherapy and tumor microenvironment improvement are achieved through the self-developing temperature-sensitive gel-drug carrying microspheres, and the anti-tumor effect is cooperatively improved.

The present invention relates to novel pharmaceutical composition comprising meloxicam for the treatment of acute pain, wherein the composition comprises at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof.

The invention relates to the field of disease animal model construction, and particularly discloses a postmenopausal osteoporosis and knee osteoarthritis co-disease animal model construction method which comprises the following steps: selecting a female animal as an experimental subject; the selected female animals are injected with a GnRH agonist, meanwhile, low-calcium feed feeding and oxidative stress stimulation are conducted, and feeding is conducted for a preset time; detecting bone mineral density and bone trabecula parameters of the fed female animals, and screening qualified female animals meeting set standards; performing meniscus tearing operation on the qualified female animal, and implanting sustained release microspheres loaded with inflammatory factors at the torn part during the operation; carrying out weight-bearing training on the female animal after the operation, and continuing for a set time length; and performing health detection on the female animals at different time points. According to the method, through multi-factor collaborative induction of the PMOP, minimally invasive construction of the KOA and multi-dimensional health detection, accurate simulation of a co-disease pathological process and clinical characteristics is realized, and the authenticity and stability of the model are improved.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The invention relates to a traditional Chinese medicine composition for treating functional dyspepsia combined with anxiety and depression and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 200-781 parts of rhizoma pinellinae praeparata, 50-365 parts of coptis chinensis, 100-521 parts of scutellaria baicalensis, 150-625 parts of rhizoma zingiberis, 50-313 parts of ginseng, 100-417 parts of liquorice, 150-625 parts of Chinese dates and 150-521 parts of immature bitter orange. The traditional Chinese medicine composition has a good effect of treating functional dyspepsia combined with anxiety and depression, and the preparation method of the traditional Chinese medicine composition is simple and suitable for large-scale production and popularization.

The invention belongs to the technical field of biological pharmacy, and particularly relates to a preparation method and application of a nano-drug carrier. The invention provides a preparation process based on a pre-polymerization-coordination-shaping sequence, which comprises the following steps: firstly, slightly combining chitosan and polyphenol under a near-neutral condition to form small particles with uniform size and good dispersity, so that adhesion among the particles is effectively reduced; then ferric ions are slowly introduced under the regulation and control of a weak chelating agent, so that the ferric ions are uniformly coordinated on the surfaces of the particles, and an inner layer which is compact in structure and has responsiveness to an acid environment or a competitive ligand is constructed; and finally, sodium alginate is introduced, crosslinking is performed through slow-release calcium ions, a flexible outer layer is formed, and the layer and the inner layer have a synergistic effect, so that the dilution resistance and the protein adsorption resistance of the carrier are remarkably enhanced.

The invention is directed to a biodegradable, thermoplastic multiblock copolymer, to a process for preparing a biodegradable, thermoplastic multiblock copolymer, to the use of a biodegradable thermoplastic multiblock copolymer, to a composition for the delivery of at least one pharmacologically active compound to a host, and a medical device comprising a biodegradable, thermoplastic multiblock copolymer. The biodegradable, thermoplastic multiblock copolymers of the invention comprise at least one prepolymer (A) segment and at least one hydrolysable amorphous prepolymer (B) segment, wherein the segments are linked by a multifunctional chain extender, wherein the at least one prepolymer (A) segment comprises: a) one or more hydrolysable linkages, b) a water-soluble polyoxazoline-based polymer, and c) reaction products of one or more cyclic monomers and / or one or more non-cyclic monomers, wherein the water-soluble polyoxazoline-based polymer is a polymer containing a repeating unit of structure −[N(COR1)CH2CH2]n− where R1 is independently selected for each repeating unit from an alkyl group and n is 3-100, and wherein the multiblock copolymer is amorphous.

The invention discloses granules of a composition containing rhizoma polygonati. The granules comprise the following components in percentage by weight: 30%-50% of composition dry paste powder, 38%-58% of a filling agent, 0.1%-20% of an adhesive and 0.1%-2% of a flow aid, the composition comprises rhizoma polygonati, fructus lycii, flos chrysanthemi and radix glehniae. Wherein the filling agent is dextrin; wherein the adhesive is maltodextrin or povidone; wherein the flow aid is colloidal silicon dioxide. According to the composition disclosed by the invention, proper auxiliary materials and an adding mode thereof are selected, so that the inherent properties of the original extract are improved, the extract is not easy to soften, the caking tendency caused by moisture absorption or heat absorption among particles is avoided, and the caking probability is reduced.

The invention discloses a traditional Chinese medicine composition with an effect of improving artery blood vessel plaque and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The technical problem to be solved is to provide a traditional Chinese medicine composition capable of improving vascular plaques such as carotid artery, aortic arch, brachial trunk, subclavian artery and the like aiming at the current situation that adverse reactions exist when statin lipid-lowering drugs and antiplatelet drugs are taken for a long time to treat artery vascular plaques. According to the technical scheme, the traditional Chinese medicine composition with the effect of improving the artery blood vessel plaque is characterized by comprising radix puerariae, red yeast rice, folium cortex eucommiae, hippophae rhamnoides leaves and natto.

The present invention aims to provide a composition having excellent anti-aging properties. [Solution] A composition characterized by containing nicotinamide mononucleotide and at least one selected from the group consisting of pine bark, banaba, and fulvic acid.

Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

The present disclosure provides daptomycin formulations which have improved chemical stability, faster reconstitution times when reconstituted from the solid state and longer in-use stability. The compositions comprise daptomycin, one basic amino acid or its salt and optionally one or more pH adjusting agents.

Compositions in homogenised powder form consisting of hydroxypropyl methylcellulose particles, and at least one chemical signalling agent in particle form, and optionally a biologically active agent, wherein the homogenised powder comprises particles having a mean particle diameter of ≥20 μm to ≤500 μmm uses and kits therefor.

The preparation method comprises the following steps: taking Cinnamomum camphora red dried orange peel decoction pieces, adding water, decocting, filtering to obtain a Cinnamomum camphora red dried orange peel extracting solution, concentrating the extracting solution to obtain clear paste, adding a proper amount of auxiliary materials into the clear paste, drying to obtain Cinnamomum camphora red dried orange peel dry paste powder, uniformly mixing the dry paste powder with a proper amount of auxiliary materials, performing dry granulation, and packaging to obtain the Cinnamomum camphora red dried orange peel formula granules. The cinnamomum camphora red tangerine peel formula granules are obtained. The invention establishes a preparation process of the Cinnamomum camphora red dried orange peel formula granules, and by mixing beta-cyclodextrin and silicon dioxide with the Cinnamomum camphora red dried orange peel clear paste before drying, the powder yield of the Cinnamomum camphora red dried orange peel dry paste powder is remarkably improved. The prepared Cinnamomum camphora red dried tangerine peel formula granules have low hygroscopicity and good formability and fluidity.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for improving obesity and metabolic syndrome and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 28 parts of radix astragali seu hedysari, 8 to 20 parts of radix codonopsis, 20 to 35 parts of rhizoma dioscoreae, 8 to 24 parts of semen lablab album, 6 to 20 parts of rhizoma atractylodis macrocephalae stir-fried with bran, 20 to 35 parts of raw semen coicis, 3 to 10 parts of rhizoma pinelliae preparata, 6 to 15 parts of pericarpium citri reticulatae, 10 to 20 parts of poria cocos, 6 to 15 parts of rhizoma alismatis, 6 to 15 parts of raw liquorice root, 10 to 20 parts of semen hoveniae, 10 to 20 parts of lotus leaf and 8 to 15 parts of raw fructus crataegi. The composition has the effects of invigorating spleen, replenishing qi, resolving dampness and removing turbidity, can effectively control the weight gain of obese patients and improve the metabolic disorder condition of metabolic syndrome, is safe, effective and stable, has small side effects, and has very good research and development values.

The application provides sodium zirconium cyclosilicate with controlled particle size distribution, which has less particles less than 3 microns, thereby improving drug safety, and has more than 95% ZS-9 crystal form, thereby having high KEC, and ensuring drug efficacy. The application further provides a preparation method and use of the sodium zirconium cyclosilicate.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

Compositions of particles having at least 95% by weight of cisplatin and a specific surface area (SSA) of at least 3.5 m2 / g. methods for their use. and methods for their production are provided.

The present disclosure relates to a porous self-healing polymer matrix for encapsulation of active macromolecules and a method of manufacturing said porous self-healing polymer matrix for a drug delivery system for a macromolecule.

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains carbidopa and about 80% to 100% of the carbidopa in the oral solid formulation is present in the one or more immediate release components.

The invention is applicable to the technical field of biomedical materials, and provides an anti-inflammatory hemostatic composite gel microsphere and a preparation method and application thereof, and the preparation method comprises the following steps: mixing sodium alginate and baicalin, dissolving in deionized water to obtain a mixed solution, spraying the mixed solution into a calcium chloride solution by utilizing electrospinning and electrospraying, and carrying out electrostatic spinning and electrospraying to obtain the anti-inflammatory hemostatic composite gel microsphere. Gel microspheres are formed through ionic crosslinking; washing the gel microspheres with a calcium chloride solution, and soaking the gel microspheres in a chitosan acetic acid solution to obtain chitosan-encapsulated gel microspheres; placing the gel microspheres in a copper sulfate solution, and performing low-temperature calcium-copper ion exchange to obtain baicalin / copper alginate composite gel microspheres; and filtering, washing and freeze-drying the composite gel microspheres. The electrospray technology is combined with ionic crosslinking, the size and morphology of the microspheres are accurately controlled, the antibacterial effect on escherichia coli and staphylococcus aureus is remarkable, the in-vitro blood coagulation time is shortened by 30%, the cytotoxicity is low, and good biocompatibility is achieved.